Tonix Pharmaceuticals offers to sell common stock, no amount given

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya(TM) product candidate in patients with fibromyalgia, and the satisfaction of any portion of its existing indebtedness. Dawson James Securities, Inc. is the sole placement agent for the offering.